BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (August 2020)

19 slides from BioSpecifics Technologies's investor presentation, Aug 11, 2020

  1. Slide 1: Building a next-generation company on the foundation of our collagenase-based therapies

    Building a next-generation company on the foundation of our collagenase-based therapies August 2020 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: Company Overview

    Company Overview (NASDAQ: BSTC) Strong cash position No debt Supported by royalty revenues from partner Endo for marketed XIAFLEX® indications Prudent cash management Continuing to maximize the XIAFLEX®/CCH portfolio XIAFLEX® commercial indications: Peyronie’s disease and Dupuytren’s contracture Qwo

  4. Slide 4: Strong Balance Sheet to Support Future Growth Initiatives

    Strong Balance Sheet to Support Future Growth Initiatives Lean corporate structure and strong balance sheet ~$119.8M in cash as of 6/30/20 $3.9M 2Q20 royalties received from Endo sales of XIAFLEX® 0 Debt Seeking to partner with companies that possess novel therapeutics that will deliver meaningful b

  5. Slide 5: Commercial and Development Pipeline

    Commercial and Development Pipeline Collagenases are naturally occurring enzymes responsible for the breakdown of collagen Biopharmaceutical company that originated and continues to develop, in collaboration with Endo Pharmaceuticals, a first-in-class collagenase-based portfolio of commercial and cl

  6. Slide 6: Multiple Conditions Associated with Collagen Accumulation

    Multiple Conditions Associated with Collagen Accumulation Dupuytren’s contracture Peyronie’s disease Medical indications, marketed as XIAFLEX® Cellulite Approved aesthetic indication, to be marketed as Qwo™ Adhesive capsulitis (frozen shoulder) Plantar fibromatosis XIAFLEX® medical indications in de

  7. Slide 7: Diverse Pipeline

    Diverse Pipeline Indication Preclinical Phase 1 Phase 2 Phase 3 Marketed XIAFLEX® COMMERCIAL INDICATIONS Dupuytren’s Contracture Peyronie’s Disease QWO™ CCH AESTHETIC INDICATION Cellulite XIAFLEX® DEVELOPMENT INDICATIONS Adhesive Capsulitis Plantar Fibromatosis Source: Endo International plc

  8. Slide 8: XIAFLEX® Commercial Indications

    XIAFLEX® Commercial Indications

  9. Slide 9: Peyronie's Disease

    Peyronie’s Disease Can distort an erection and make sexual intercourse difficult or even impossible in advanced cases In some mild cases, the plaque can resolve spontaneously without medical intervention In severe cases, the penis can be bent at a 90-degree angle during erection Characterized by pre

  10. Slide 10: Dupuytren's Contracture

    Dupuytren’s Contracture Onset is characterized by the formation of nodules at the juncture between the fingers and palm that are composed primarily of collagen As the disease progresses, collagen nodules begin to form a cord causing the patient’s finger(s) to contract, making it impossible to open t

  11. Slide 11: Qwo™ Aesthetic Indication

    Qwo™ Aesthetic Indication S biospecifics

  12. Slide 12: Qwo™ for Cellulite

    Qwo™ for Cellulite Affects ~85-90% of post-pubertal females First FDA-approved pharmaceutical product to address fibrous septae primarily composed of collagen Skin dimpling occurring mainly on the buttocks, thighs and lower abdomen and arms FDA Status Approved July 2020 Commercial launch anticipated

  13. Slide 13: XIAFLEX® Development Pipeline

    XIAFLEX® Development Pipeline

  14. Slide 14: Adhesive Capsulitis

    Adhesive Capsulitis Common available treatment options are often painful and can require anesthesia Long-term intensive physical therapy, corticosteroids, manipulation under anesthesia and /or arthroscopic release Condition can last ~1 year to up to 3.5 years Inflammation and thickening of shoulder

  15. Slide 15: Plantar Fibromatosis

    Plantar Fibromatosis Formation of nodules or cords along plantar fascia Patients often have Dupuytren’s disease, Peyronie’s disease and adhesive capsulitis Pain and disability caused by the thickening of the feet's deep connective tissue Market Opportunity ~3-3.5M patients with plantar fasciitis or

  16. Slide 16: BSTC Corporate Overview

    BSTC Corporate Overview S biospecifics

  17. Slide 17: Financial Highlights from 2Q20

    Financial Highlights from 2Q20 For the three months ended 6/30/2020 6/30/2019 Cash and equivalents, and investments $119,843,584 $93,509,884 Income Statement Revenues $ 3,903,402 $8,852,986 Other income 390,888 517,156 Costs and expenses (4,154,322) (1,889,446) Provision for income taxes (24,172) (1

  18. Slide 18: Corporate Outlook and Upcoming Milestones

    Corporate Outlook and Upcoming Milestones Continue to receive royalty revenues from partner Endo for marketed XIAFLEX® indications Royalty revenue decreased 56% year-over-year for 2Q20 Endo expects full year 2020 revenues to be lower than 2019 due to COVID-19 IP through 2028 Opportunistic about Busi

  19. Slide 19: Building a next-generation company on the foundation of our collagenase-based therapies

    Building a next-generation company on the foundation of our collagenase-based therapies August 2020

Biospecifics Technologies — Investor Presentation (August 2020) on 6ix